University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Antibody-Drug Conjugates for Cancer Therapy

    Thumbnail
    Download
    published version (1.973Mb)

    Citations
    Altmetric
    Author
    Hafeez, U; Parakh, S; Gan, HK; Scott, AM
    Date
    2020-10-01
    Source Title
    Molecules
    Publisher
    MDPI
    University of Melbourne Author/s
    Scott, Andrew; Gan, Hui; Hafeez, Umbreen
    Affiliation
    Medicine and Radiology
    Medical Education
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Hafeez, U., Parakh, S., Gan, H. K. & Scott, A. M. (2020). Antibody-Drug Conjugates for Cancer Therapy. MOLECULES, 25 (20), https://doi.org/10.3390/molecules25204764.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/251739
    DOI
    10.3390/molecules25204764
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587605
    Abstract
    Antibody-drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [52443]
    • Medical Education - Research Publications [594]
    • Medicine and Radiology - Research Publications [3310]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors